Results 11 to 20 of about 13,466 (213)
Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. [PDF]
Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product, Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of ...
Maarten van Dinther +10 more
doaj +8 more sources
Sclerostin and Vascular Pathophysiology [PDF]
There is cumulating evidence for a contribution of Wnt signaling pathways in multiple processes involved in atherosclerosis and vascular aging. Wnt signaling plays a role in endothelial dysfunction, in the proliferation and migration of vascular smooth muscle cells (VSMCs) and intimal thickening.
Catalano A. +3 more
openaire +4 more sources
Sclerostin and Cardiovascular Disease
Abstract Purpose of Review The role of wnt signalling in atherogenesis raises the possibility that the wnt inhibitor, sclerostin, provides a natural defence to this process, and that anti-sclerostin antibodies might increase the risk of atherosclerosis and associated conditions such as CVD.
Tobias, Jonathan H, Jonathan H. Tobias
openaire +4 more sources
The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.
Stuart L. Silverman
openaire +5 more sources
Role of Sclerostin in Cardiovascular Disease
Sclerostin is most recognized for its role in controlling bone formation but is also expressed in the heart, aorta, coronary, and peripheral arteries. This review summarizes research on sclerostin’s role in cardiovascular disease. Rodent studies have found sclerostin to be expressed at sites of arterial calcification.
Jonathan Golledge +1 more
openaire +4 more sources
The Role of Sclerostin in Bone Diseases [PDF]
Sclerostin has been identified as an important regulator of bone homeostasis through inhibition of the canonical Wnt-signaling pathway, and it is involved in the pathogenesis of many different skeletal diseases. Many studies have been published in the last few years regarding sclerostin’s origin, regulation, and mechanism of action.
Elias S. Vasiliadis +5 more
core +5 more sources
Therapeutic antibody against sclerostin loop2 promoted bone formation in postmenopausal osteoporosis but caused severe cardiovascular events in clinical applications.
Luyao Wang +27 more
doaj +3 more sources
Role of Sclerostin in Cardiovascular System
Sclerostin, encoded by the SOST gene, is a novel bone anabolic target for bone diseases. Humanized anti-sclerostin antibody, romosozumab, was approved for treatment of postmenopausal osteoporosis by the US Food and Drug Administration (FDA), but with a black-box warning on cardiovascular risk.
Ning Zhang +11 more
openaire +3 more sources
Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis
Arti D Shah,1 Dolores Shoback,1,2 E Michael Lewiecki3,4 1Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Francisco, CA, USA; 2Endocrine Research Unit, Department of Medicine, Veterans Affairs Medical ...
Shah AD, Shoback D, Lewiecki EM
doaj +1 more source
Sclerostin and occlusion: A brief review
In its pursuit of understanding the wonders of human body, mankind has stumbled upon yet another discovery which not only is a key to chest of unanswered queries but also opens a plethora of new possibilities. Till recently the osteocytes were considered latent cells merely entrapped in the matrix of bone. With the discovery of beta-catenin pathway and
Pankaj Bansal +3 more
openaire +4 more sources

